Boston Society’s 11th Annual Applied Pharmaceutical Analysis conference-Reference-Cited by-同舟云学术

Boston Society’s 11th Annual Applied Pharmaceutical Analysis conference

Published:2016-02 Issue:4 Volume:8 Page:259-264
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Lee Violet¹,Liu Ang²,Groeber Elizabeth³,Moghaddam Mehran⁴,Schiller James⁵,Tweed Joseph A⁶,Walker Gregory S⁶

Affiliation:

1. Genentech, Inc., South San Francisco, CA, USA

2. Bristol–Myers Squibb, Analytical & Bioanalytical Development, Princeton, NJ, USA

3. WIL Research, Ashland, OH, USA

4. Celgene Corp., Discovery DMPK, San Diego, CA, USA

5. Merck & Co., Regulated Bioanalytical – PPDM, West Point, PA, USA

6. Pfizer, Inc., Worldwide Pharmacokinetics & Metabolism – NCE, Groton, CT, USA

Abstract

Boston Society's 11th Annual Applied Pharmaceutical Analysis conference, Hyatt Regency Hotel, Cambridge, MA, USA, 14–16 September 2015 The Boston Society’s 11th Annual Applied Pharmaceutical Analysis (APA) conference took place at the Hyatt Regency hotel in Cambridge, MA, on 14–16 September 2015. The 3-day conference affords pharmaceutical professionals, academic researchers and industry regulators the opportunity to collectively participate in meaningful and relevant discussions impacting the areas of pharmaceutical drug development. The APA conference was organized in three workshops encompassing the disciplines of regulated bioanalysis, discovery bioanalysis (encompassing new and emerging technologies) and biotransformation. The conference included a short course titled ‘Bioanalytical considerations for the clinical development of antibody–drug conjugates (ADCs)’, an engaging poster session, several panel and round table discussions and over 50 diverse talks from leading industry and academic scientists.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio.15.250

Reference20 articles.

1. US FDA-center for drug evaluation-office of translational sciences-office of study integrity and surveillance-division of generic drug bioequivalence evaluation? www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm119463.htm

2. USC 262. Regulation of biological products, from Title 42 – The Public Health and Welfare. http://uscode.house.gov/view.xhtml?req=(title:42%20section:262%20edition:prelim)

3. Database of CGMP facilities and bioequivalence sites. www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/default.htm

4. US FDA-center for drug evaluation-office of translational sciences-office of study integrity and surveillance. www.fda.gov/AboutFDA/CentersOffices/OrganizationCharts/ucm437914.htm

5. An overview of FDA-approved biologics medicines

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Welcome to volume 9 of Bioanalysis;Bioanalysis;2017-01